Skip to Main Content
Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
YSM Home

INFORMATION FOR

Kevan Herold, MD

C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)
DownloadHi-Res Photo

Clinical Specialties

Endocrinology, Pediatric Endocrinology & Diabetes + 1 more
Patients Treated
Child, Adult

About

Titles

C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)

Biography

My background and research are in translational immunology. I am interested in understanding the basis for autoimmune diseases and developing new therapies based on our understanding of disease mechanisms. My focus has largely been in the field of autoimmune Type 1 diabetes. The work encompasses basic laboratory work as well as clinical studies to understanding the regulation of autoreactive T cells to clinical trials that involve novel therapeutics. As part of these studies my lab has been very interested in analysis of beta cell function in Type 1 diabetes and identifying the cellular mechanisms that can protect them from immune killing. We have also been studying the development of autoimmune diabetes in patients with cancers who are treated with checkpoint inhibitors. Our clinical and basic studies are focused on understanding how beta cells are destroyed and react to inflammation. Finally, with the COVID-19 pandemic, we have been studying the immunologic basis for responses in children and adults who are hospitalized with COVID-19 to understand the mechanisms that can lead to disease protection.

Appointments

  • Endocrinology

    Professor
    Fully Joint

Other Departments & Organizations

  • Cancer Immunology
  • Diabetes Center
  • Diabetes Research Center
  • Endocrinology
  • Fellowship Training
  • Herold Lab
  • Human and Translational Immunology Program
  • Immunobiology
  • Immunology
  • Internal Medicine
  • NIH T32 Program
  • Rheumatic Diseases Research Core
  • Yale Cancer Center
  • Yale Center for Systems and Engineering Immunology (CSEI)
  • Yale Combined Program in the Biological and Biomedical Sciences (BBS)
  • Yale Medicine
  • Yale Stem Cell Center
  • Yale Ventures

Education & Training

Fellow
University of Chicago (1984)
Residency
Temple University Hospital (1982)
MD
Jefferson Medical College (1979)
BS
Pennsylvania State University (1977)

Research

Overview

The pathogenesis and treatment of autoimmune disease, in particular Type 1 diabetes.

Studies involve clinical trials with patients and investigations of the mechanism of action of immune therapies and the pathogenesis of disease in patients as well as in animal models when needed to address what cannot be studies in humans. Over the past 7 years, our lab has carried out trials of a humanized non-FcR binding anti-CD3 monoclonal antibody in patients and has studied the mechanism of drug action. These clinical studies have suggested novel mechanisms of immune regulation that are now to be addressed with new clinical studies.

Medical Research Interests

Autoimmunity; Diabetes Mellitus, Type 1; Endocrine System Diseases; Immune System Diseases; Metabolism; Polyendocrinopathies, Autoimmune; Translational Research, Biomedical

Public Health Interests

Metabolism; Immunology

Research at a Glance

Yale Co-Authors

Frequent collaborators of Kevan Herold's published research.

Publications

2024

See All Publications

Clinical Trials

Current Trials

See All Current Clinical Trials

Clinical Care

Overview

Kevan Herold, MD, is an endocrinologist who treats adult and child patients with type 1 and type 2 diabetes, diabetes that occurs after therapies for cancer, and hypoglycemia (low blood glucose levels).

Type 1 diabetes is an autoimmune disease that is often diagnosed in children and teens. The immune system mistakenly attacks healthy body tissues and destroys cells in the pancreas that produce insulin.

Dr. Herold’s goal is to better understand the mechanisms for type 1 diabetes in order to develop new treatments for his patients. His research revolves around beta cell function. In type 1 diabetes, beta cells produce little or no insulin and are destroyed by T cells from the immune system. Dr. Herold and his lab also research autoimmune diabetes development in cancer patients.

Recently, Dr. Herold was the principal investigator for a clinical trial that showed the effectiveness of teplizumab, a new drug that could delay type 1 diabetes development by two years. He is chair of NIDDK (National Institute of Diabetes and Digestive Diseases) TrialNet, an international network of type 1 diabetes researchers.

Dr. Herold is C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology) at Yale School of Medicine.

Clinical Specialties

Endocrinology; Pediatric Endocrinology & Diabetes; Diabetes Medicine & Management

Fact Sheets

See All Fact Sheets On Yale Medicine

Board Certifications

  • Endocrinology & Metabolism

    Certification Organization
    AB of Internal Medicine
    Original Certification Date
    1985

  • Internal Medicine

    Certification Organization
    AB of Internal Medicine
    Original Certification Date
    1982

Yale Medicine News

See All News On Yale Medicine

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Get In Touch

Contacts

Email
Academic Office Number
Appointment Number
Clinic Fax Number

Administrative Support

Locations

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    See Patient Care Locations

Events

Apr 20258Tuesday